北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease ABSORB China Trial
作者: Gao, Runlin1; Yang, Yuejin1; Han, Yaling2; Huo, Yong3; Chen, Jiyan4; Yu, Bo5; Su, Xi6; Li, Lang7; Kuo, Hai-Chien8; Ying, Shih-Wa8; Cheong, Wai-Fung8; Zhang, Yunlong8; Su, Xiaolu8; Xu, Bo1; Popma, Jeffery J.9; Stone, Gregg W.10,11; ABSORB China Investigators
关键词: bioresorbable vascular scaffold ; everolimus ; randomized controlled trial ; stent
刊名: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
发表日期: 2015-12-01
DOI: 10.1016/j.jacc.2015.09.054
卷: 66, 期:21, 页:2298-2309
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: DRUG-ELUTING STENTS ; RANDOMIZED-TRIALS ; END-POINTS ; OUTCOMES ; DEVICES ; IMPACT
英文摘要:

BACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established.

OBJECTIVES This study sought to evaluate the angiographic efficacy and clinical safety and effectiveness of BVS in a randomized trial designed to enable approval of the BVS in China.

METHODS Eligible patients with 1 or 2 de novo native coronary artery lesions were randomized to BVS or cobalt-chromium everolimus-eluting stents (CoCr-EES) in a 1: 1 ratio stratified by diabetes and the number of lesions treated. Angiographic and clinical follow-up were planned at 1 year in all patients. The primary endpoint was angiographic in-segment late loss (LL), powered for noninferiority with a margin of 0.15 mm.

RESULTS A total of 480 patients were randomized (241 BVS vs. 239 CoCr-EES) at 24 sites. Acute clinical device success (98.0% vs. 99.6%; p = 0.22) and procedural success (97.0% and 98.3%; p = 0.37) were comparable in BVS- and CoCr-EES-treated patients, respectively. The primary endpoint of in-segment LL at 1 year was 0.19 +/- 0.38 mm for BVS versus 0.13 +/- 0.38 mm for CoCr-EES; the 1-sided 97.5% upper confidence limit of the difference was 0.14 mm, achieving noninferiority of BVS compared with CoCr-EES (P-noninferiority = 0.01). BVS and CoCr-EES also had similar 1-year rates of target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization; 3.4% vs. 4.2%, respectively; p = 0.62) and definite/probable scaffold/stent thrombosis (0.4% vs. 0.0%, respectively; p = 1.00).

CONCLUSIONS In the present multicenter randomized trial, BVS was noninferior to CoCr-EES for the primary endpoint of in-segment LL at 1 year. (A Clinical Evaluation of Absorb Bioresorbable Vascular Scaffold [Absorb BVS] System in Chinese Population-ABSORB CHINA Randomized Controlled Trial [RCT]; NCT01923740) (C) 2015 by the American College of Cardiology Foundation.

语种: 英语
WOS记录号: WOS:000365099600005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55613
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Abbott Vasc, Santa Clara, CA USA
2.Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
3.Cardiovasc Res Fdn, New York, NY USA
4.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
5.Wuhan Asia Heart Hosp, Wuhan, Peoples R China
6.Shenyang Mil Reg, Gen Hosp, Shenyang, Peoples R China
7.Peking Univ, Hosp 1, Beijing 100871, Peoples R China
8.Chinese Acad Med Sci, Fu Wai Hosp, Natl Ctr Cardiovasc Dis, Beijing 100037, Peoples R China
9.Harbin Med Univ, Affiliated Hosp 2, Key Lab Myocardial Ischemia, Chinese Minist Educ, Harbin, Peoples R China
10.Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
11.Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA

Recommended Citation:
Gao, Runlin,Yang, Yuejin,Han, Yaling,et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease ABSORB China Trial[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,2015,66(21):2298-2309.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Gao, Runlin]'s Articles
[Yang, Yuejin]'s Articles
[Han, Yaling]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Gao, Runlin]‘s Articles
[Yang, Yuejin]‘s Articles
[Han, Yaling]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace